Roche Launches Cobas Eplex RP3 In CE Markets, Featuring First Flexible Syndromic Testing With Up To 5 Customisable Panels For Local Needs

Roche has launched the Cobas Eplex RP3 test in CE markets, which can detect up to 250 viruses and bacteria, including SARS-CoV-2 and influenza, from a single patient sample. This test is designed for the cobas eplex system and provides rapid results, enabling healthcare providers to make timely treatment decisions for high-risk patients. The product aims to assist hospitals in managing increased respiratory case loads effectively.